Drugs / ZOTIZALKIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04849273 | Jul 2021 → Apr 2023 | metastatic neoplasm, non-small cell lung carcinoma | Turning Point Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZOTIZALKIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314412 ↗ |
| Known as | TPX-0131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849273 ↗ |
| Action | Inhibit | “novel ALK inhibitor TPX-0131” NCT04849273 ↗ |
| Modality | Small molecule | — CHEMBL5314412 ↗ |
| Route | Oral | “Oral TPX-0131 tablets” NCT04849273 ↗ |
| Target | ALK | “novel ALK inhibitor TPX-0131” NCT04849273 ↗ |